Saturday, October 23, 2021

Scientists Develop New Nanoparticle for Intravenous Cancer Immunotherapy - AZoNano

Last updated Friday, October 1, 2021 10:48 ET , Source: NewsService

Cancer immunotherapy aims to change “cold” tumors into “hot” tumors – those that react to immunotherapy – by stimulating and enlisting the immune system of the body.

Regrettably, few people gain from the most frequently used form of immunotherapy, known as immune checkpoint inhibitors, and researchers are keenly seeking new and harmless molecules called agonists to boost the immune response of the body. The STING agonist is one potential drug in clinical trials. STING is a protein critical to the immune response against contagion as well as cancer.

In hunting for molecules that would boost the STING pathway, researchers at the University of Michigan’s College of Pharmacy and the Rogel Cancer Center chose nutritional metal ions, which humans absorb from food and are vital for immune regulation.

They learned that incorporating the nutritional metal ion manganese to STING agonists enhanced STING’s capability to fight tumors by nearly 77-fold, compared to STING agonists used in isolation, said James Moon, the J.G. Searle Professor of Pharmaceutical Sciences and professor of biomedical engineering.

When scientists incorporated the manganese ions into STING agonists, they created nano-sized crystals, which considerably boosted cellular uptake of STING agonists and STING activation by immune cells. To develop a STING agonist for intravenous administration, the team coated these nanocrystals with a lipid layer (akin to those used in mRNA COVID19 vaccines), resulting in a...

Read Full Story: https://www.azonano.com/news.aspx?newsID=38176

Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.